McCleary Kaci, Barrash Joseph, Granner Mark, Manzel Kenneth, Greider Audrey, Jones Robert
Department of Neurology, University of Iowa, United States.
Department of Neurology, University of Iowa, United States.
Epilepsy Behav. 2018 Jan;78:25-29. doi: 10.1016/j.yebeh.2017.10.037. Epub 2017 Nov 21.
The intracarotid sodium amytal procedure (the "Wada test") has for many years been the gold standard for language and memory lateralization and remains an important part of presurgical analysis for patients with medically intractable seizures. Due to shortages in the key sedative (amobarbital), neuropsychologists have turned to alternatives such as propofol. Our aim was to investigate the safety and efficacy of propofol relative to amobarbital in the Wada test.
We performed a retrospective review of the 97 Wada procedures performed at University of Iowa Hospitals and Clinics from 2007 through mid-2015.
Propofol produced similar lateralization rates as amobarbital for both language and memory. Similar rates of patients in each group went on to have the resection surgery. With regard to safety, there were no differences found in average rate or severity of adverse effects. None of the demographic characteristics reviewed were predictive of increased risk for either drug.
These findings support previous studies indicating that propofol is as safe and efficacious as amobarbital, and can continue to be used in Wada procedures with confidence.
颈内动脉注射异戊巴比妥钠试验（“Wada试验”）多年来一直是语言和记忆功能定侧的金标准，并且仍是药物难治性癫痫患者术前分析的重要组成部分。由于关键镇静剂（异戊巴比妥）短缺，神经心理学家已转向丙泊酚等替代药物。我们的目的是研究在Wada试验中丙泊酚相对于异戊巴比妥的安全性和有效性。
我们对2007年至2015年年中在爱荷华大学医院及诊所进行的97例Wada试验进行了回顾性研究。
丙泊酚在语言和记忆功能定侧方面产生的比率与异戊巴比妥相似。每组中进行切除手术的患者比率相似。在安全性方面，未发现不良反应的平均发生率或严重程度存在差异。所审查的人口统计学特征均不能预测两种药物的风险增加。
这些发现支持了先前的研究，表明丙泊酚与异戊巴比妥一样安全有效，并且可以继续放心地用于Wada试验。
